NCT07140679View on ClinicalTrials.gov

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 19, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

December 31, 2029

Conditions
Localized Colon CarcinomaStage IIB Colon Cancer AJCC v8Stage IIC Colon Cancer AJCC v8Stage III Colon Cancer AJCC v8
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Colonoscopy

Undergo colonoscopy

PROCEDURE

Computed Tomography

Undergo CT

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Toripalimab

Given IV

Trial Locations (5)

30033

RECRUITING

Emory Decatur Hospital, Atlanta

30097

RECRUITING

Emory Johns Creek Hospital, Johns Creek

30308

RECRUITING

Emory University Hospital Midtown, Atlanta

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

RECRUITING

Emory Saint Joseph's Hospital, Atlanta

Sponsors

Collaborators (1)

Coherus Oncology, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Coherus Oncology, Inc.

INDUSTRY

lead

Emory University

OTHER

NCT07140679 - Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer | Biotech Hunter | Biotech Hunter